ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 575,44
-0,75%
Dow Jones
40 211,72
0,53%
DAX
18 508,17
-0,49%
Brent Oil
83,255
-1,29%
Bitcoin
63 690,06
-1,79%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Portola Pharmaceuticals Inc (PTLA)

  7. Portola Pharmaceuticals Inc (PTLA) Actualités

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
24/04/201822h28Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
13/04/201812h07Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:PTLAPortola Pharmaceuticals Inc
04/04/201814h30GlobeNewswire Inc.Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:PTLAPortola Pharmaceuticals Inc
30/03/201823h25Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTLAPortola Pharmaceuticals Inc
23/03/201814h06GlobeNewswire Inc.Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban i...NASDAQ:PTLAPortola Pharmaceuticals Inc
21/03/201800h39Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTLAPortola Pharmaceuticals Inc
12/03/201817h12GlobeNewswire Inc.Portola Pharmaceuticals Announces New Interim Results from Ongoing ANNEXA-4 Study of Factor Xa Inhibitor Reversal Agent Andex...NASDAQ:PTLAPortola Pharmaceuticals Inc
12/03/201813h30GlobeNewswire Inc.Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General CounselNASDAQ:PTLAPortola Pharmaceuticals Inc
06/03/201822h05GlobeNewswire Inc.Portola Pharmaceuticals to Present at Two Upcoming Investor ConferencesNASDAQ:PTLAPortola Pharmaceuticals Inc
05/03/201822h10GlobeNewswire Inc.Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highli...NASDAQ:PTLAPortola Pharmaceuticals Inc
28/02/201822h40Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
28/02/201822h05GlobeNewswire Inc.Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
20/02/201822h47GlobeNewswire Inc.Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and BetrixabanNASDAQ:PTLAPortola Pharmaceuticals Inc
15/02/201822h05GlobeNewswire Inc.Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesda...NASDAQ:PTLAPortola Pharmaceuticals Inc
14/02/201823h15Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
12/02/201816h01Edgar (US Regulatory)Schedule 13gNASDAQ:PTLAPortola Pharmaceuticals Inc
23/01/201803h33GlobeNewswire Inc.Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18NASDAQ:PTLAPortola Pharmaceuticals Inc
22/12/201723h23GlobeNewswire Inc.Portola Pharmaceuticals Provides Update on Biologics License Application (BLA) for AndexXa® (andexanet alfa)NASDAQ:PTLAPortola Pharmaceuticals Inc
22/12/201714h00GlobeNewswire Inc.Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018NASDAQ:PTLAPortola Pharmaceuticals Inc
19/12/201716h35GlobeNewswire Inc.U.S. Food and Drug Administration Approves Prior Approval Supplement for Commercial Launch of Portola Pharmaceuticals’ Nove...NASDAQ:PTLAPortola Pharmaceuticals Inc
12/12/201714h30GlobeNewswire Inc.Portola Pharmaceuticals Provides Update on European Marketing Authorization Application for BetrixabanNASDAQ:PTLAPortola Pharmaceuticals Inc
05/12/201722h14GlobeNewswire Inc.Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:PTLAPortola Pharmaceuticals Inc
30/11/201714h00GlobeNewswire Inc.Portola Pharmaceuticals to Present New Data on Betrixaban, Andexanet Alfa and Cerdulatinib at the 59th American Society of He...NASDAQ:PTLAPortola Pharmaceuticals Inc
22/11/201700h22GlobeNewswire Inc.Portola Pharmaceuticals Provides Update on Bevyxxa® (betrixaban) Commercial LaunchNASDAQ:PTLAPortola Pharmaceuticals Inc
09/11/201723h11Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PTLAPortola Pharmaceuticals Inc
09/11/201712h09Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
07/11/201714h00GlobeNewswire Inc.Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Associa...NASDAQ:PTLAPortola Pharmaceuticals Inc
06/11/201722h01GlobeNewswire Inc.Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
06/11/201714h00GlobeNewswire Inc.Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President of Product Development and...NASDAQ:PTLAPortola Pharmaceuticals Inc
03/11/201713h00GlobeNewswire Inc.Portola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare ConferenceNASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA

Dernières Valeurs Consultées

BOV
CSNA3
SID NACIONAL ON
NASDAQ
RXST
RxSight
LSE
PHSC
Phsc
NASDAQ
PTIX
Protagenic Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés